Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts give Recursion an average consensus rating of "Hold" from five brokers (1 sell, 2 hold, 2 buy) with a mean 12-month target of $9.40 and price targets ranging roughly $6–$11.
• The company beat the latest quarterly estimates (EPS -$0.21 vs. -$0.28; revenue $35.54M vs. $24.56M), showing revenue up 671.7% year-over-year, but remains deeply unprofitable (net margin -863.37% and negative PE).
• Shares traded down to $3.01 (down ~4.6%) near a 52-week low of $2.98 with a $1.58B market cap, while insiders have been selling (CEO and CFO recent sales; 511,063 shares sold in the last 90 days) and institutional ownership is high at ~89%.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has received an average rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $9.40.

A number of analysts have issued reports on the company. Wall Street Zen raised Recursion Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday, February 28th. Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Bank of America cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th.

Recursion Pharmaceuticals Stock Down 4.6%

Recursion Pharmaceuticals stock traded down $0.15 during trading on Friday, reaching $3.01. The stock had a trading volume of 4,422,575 shares, compared to its average volume of 18,748,900. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 52-week low of $2.98 and a 52-week high of $7.18. The stock has a market cap of $1.58 billion, a PE ratio of -2.03 and a beta of 0.97. The business has a 50 day moving average price of $3.77 and a 200 day moving average price of $4.49.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. The business had revenue of $35.54 million for the quarter, compared to analyst estimates of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company's revenue was up 671.7% on a year-over-year basis. During the same period last year, the business earned ($0.53) EPS. On average, analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $3.35, for a total transaction of $94,798.30. Following the sale, the chief executive officer owned 2,262,085 shares in the company, valued at approximately $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Ben R. Taylor sold 7,956 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the completion of the sale, the chief financial officer directly owned 1,180,318 shares of the company's stock, valued at approximately $4,001,278.02. This trade represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 511,063 shares of company stock valued at $2,135,702 over the last ninety days. Insiders own 8.43% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently modified their holdings of RXRX. Hsbc Holdings PLC raised its position in Recursion Pharmaceuticals by 537.3% in the 4th quarter. Hsbc Holdings PLC now owns 818,316 shares of the company's stock valued at $3,367,000 after purchasing an additional 689,903 shares during the last quarter. Fund Advisors of America Inc FL acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at $82,000. Corient Private Wealth LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $70,000. Invesco Ltd. boosted its stake in shares of Recursion Pharmaceuticals by 25.8% during the fourth quarter. Invesco Ltd. now owns 526,144 shares of the company's stock worth $2,152,000 after buying an additional 107,979 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its holdings in shares of Recursion Pharmaceuticals by 55.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 25,020 shares of the company's stock worth $100,000 after buying an additional 8,935 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.